An observational study in Bipolar Disorder, sponsored by AstraZeneca. Completed at 24 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-30.
Sponsored by AstraZeneca · Observational
The purpose of this study is to estimate adherence to treatment in bipolar patients, to characterize patients based on adherence degree and to describe the variables linked to poor adherence to treatment in real-life practice.
1,601 studies on the registry are indexed under Bipolar Disorder; 254 are open to participants now.
This study's planned enrollment of 300 is above the median of 160 across 329 observational studies indexed under Bipolar Disorder.
Browse Bipolar Disorder studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
Exclusion Criteria:
Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
Morisky-Green Scale
Time frame: Once, at the visit moment
Drug Attitude Inventory Scale (DAI-10)
Time frame: Once, at the visit moment
Clinical Global Impressions for Bipolar illness-modified (CGI-BP-M)
Time frame: Once, at the visit moment
Functioning Assessment Short Test (FAST)
Time frame: Once, at the visit moment
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca